Pretreatment lactate dehydrogenase, but not magnesium or neutrophil-to-lymphocyte ratio, is independently associated with grade ≥3 chemotherapy toxicity in breast cancer: prediction-model development and internal validation in 400 patients
Pretreatment lactate dehydrogenase, but not magnesium or neutrophil-to-lymphocyte ratio, is independently associated with grade ≥3 chemotherapy toxicity in breast cancer: prediction-model development and internal validation in 400 patients. // Cancer Treatment and Research Communications. – URL: https://www.sciencedirect.com/science/article/pii/S2468294226003709?dgcid=rss_sd_all
Pretreatment lactate dehydrogenase, but not magnesium or neutrophil-to-lymphocyte ratio, is independently associated with grade ≥3 chemotherapy toxicity in breast cancer: prediction-model development and internal validation in 400 patients. Cancer Treatment and Research Communications. https://www.sciencedirect.com/science/article/pii/S2468294226003709?dgcid=rss_sd_all
“Pretreatment lactate dehydrogenase, but not magnesium or neutrophil-to-lymphocyte ratio, is independently associated with grade ≥3 chemotherapy toxicity in breast cancer: prediction-model development and internal validation in 400 patients.” Cancer Treatment and Research Communications.
@article{article116551,
title = {Pretreatment lactate dehydrogenase, but not magnesium or neutrophil-to-lymphocyte ratio, is independently associated with grade ≥3 chemotherapy toxicity in breast cancer: prediction-model development and internal validation in 400 patients},
journal = {Cancer Treatment and Research Communications},
url = {https://www.sciencedirect.com/science/article/pii/S2468294226003709?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment